The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

Address: Pharmaceutical Sciences Department, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.; 1] Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver, Colorado, USA [2] Clinical Pharmacy Services, Kaiser Permanente Colorado, Denver, Colorado, USA.; Department of Medicine, Duke University, Durham, North Carolina, USA.; 1] IMAGENETICS, Sanford Medical Center, Fargo, North Dakota, USA [2] Department of Medicine, University of North Dakota, Fargo, North Dakota, USA.; Department of Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy, Columbia, South Carolina, USA.; Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida, USA.; Atherosclerosis Research, Children's Hospital Oakland Research Institute, Oakland, California, USA.; 1] Oates Institute for Experimental Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee, USA [2] Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.; Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida, USA.; Department of Genetics, Stanford University, Palo Alto, California, USA.; Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.; 1] Department of Clinical Pharmacology, University of Helsinki and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland [2] King Abdulaziz University , Jeddah, Saudi Arabia.